INOVIO (INO) announced plans to submit a BLA for INO-3107 as a potential treatment for Recurrent Respiratory Papillomatosis in the second half of 2024. This followed an Initial Comprehensive Multidisciplinary Breakthrough Therapy Meeting with the FDA on critical aspects of the data package required to submit a BLA under the accelerated approval program.